Polypeptide Derivative for Hepatopathy via GHS-R Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatopathy, such as hepatitis, liver cirrhosis, and hepatic insufficiency, lack effective therapeutic agents that can promote hepatocyte proliferation and improve hepatic function recovery, especially after liver operations like hepatectomy or transplantation, where hepatic function abnormalities are common and challenging to manage.
Innovation Solution
A polypeptide derivative that binds to the growth hormone secretagogue receptor (GHS-R), elevating intracellular calcium ion concentration, is developed as a therapeutic agent to prevent, treat, or promote hepatic regeneration and function recovery in hepatopathy, including specific amino acid sequences or modified versions thereof.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (glycyrrhizin, glutathione, vitamins) are used for hepatopathy, then basic hepatic function support is provided, but effective promotion of hepatocyte proliferation and hepatic function recovery is not achieved
Solution Approach 1:
The patent uses growth hormone secretagogues that bind to GHS-R receptors to change the physiological parameters of hepatocytes, triggering intracellular signaling cascades (increasing intracellular calcium and cAMP levels) that promote cell proliferation and functional recovery, thereby resolving the contradiction between providing basic support and actively promoting regeneration
2Object-affected harmful factors
If interferon is used for viral hepatitis, then antiviral effect is achieved, but severe side effects (including suicide) occur and it is not effective for all hepatitis patients
Solution Approach 1:
The patent introduces growth hormone secretagogues as an intermediary substance that acts through GHS-R receptors to promote hepatic regeneration and function recovery. This mediator provides a different therapeutic pathway that avoids the severe side effects of interferon while still treating hepatitis, particularly by enhancing the liver's self-repair capabilities rather than directly attacking the virus
3Object-affected harmful factors
If surgical treatment (hepatectomy or living-donor liver transplantation) is performed, then liver cancer or severe hepatopathy is treated, but reduction or abnormality in hepatic function is observed after operation
Solution Approach 1:
The patent applies growth hormone secretagogues before and after surgical treatment to preliminarily enhance hepatocyte proliferation capacity and subsequently accelerate post-operative hepatic function recovery. This preliminary and follow-up action prevents the reduction in hepatic function that typically occurs after hepatectomy or transplantation by stimulating the remaining liver tissue to regenerate more effectively
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polypeptide derivative effectively promotes hepatocyte proliferation and improves hepatic function, addressing the reduction in hepatic function post-liver operations and providing a therapeutic option for hepatopathy, including hepatitis and liver cirrhosis.
Implementation Method 1
a polypeptide derivative having an activity of binding to growth hormone secretagogue receptor (hereinafter, abbreviated as GHS-R) and thus elevating intracellular calcium ion concentration
Data Source
AI summary
The present invention relates to a preventive or a therapeutic agent for hepatopathy, comprising, as an effective ingredient, a polypeptide derivative having an activity of binding to growth hormone secretagogue receptor and thus elevating intracellular calcium ion concentration, and having one amino acid sequence selected from the group consisting of amino acid sequences represented by SEQ ID NOS: 1 to 22, or an amino acid sequence in which one to several amino acids are deleted, substituted or added at the amino acid residues other that the first to forth amino acid residues from the amino-terminus in the said amino acid sequence, or a pharmacologically acceptable salt thereof. The preventive or the therapeutic agent for hepatopathy in accordance with the present invention is useful as a drug suitable for treating or preventing hepatic diseases such as hepatitis, liver cirrhosis and hepatic insufficiency. Further, the preventive or the therapeutic agent for hepatopathy in accordance with the present invention is also useful as an agent of promoting hepatic regeneration and hepatic function recovery after hepatectomy.